Non-THC Cannabis Compound Tied to Weight Loss in New Study

By VirentaNews Staff — May 18, 2026

For decades, cannabis has been stereotypically linked to increased appetite and weight gain, epitomized by the phenomenon of “the munchies.” However, a recent study reveals that one of its lesser-known compounds—cannabigerol, or CBG—may do the exact opposite. In mouse trials, CBG administration led to a 30% reduction in food intake and significant body weight loss over a week, without apparent adverse effects. Unlike THC, CBG does not produce psychoactive effects, making it a particularly attractive candidate for therapeutic use. These findings, published in the journal Life Sciences, suggest that the plant’s metabolic influence is far more complex than previously understood, and could open new frontiers in the treatment of obesity and metabolic disorders affecting over 650 million adults worldwide, according to the World Health Organization.

The Rise of Minor Cannabinoids in Medical Research

While THC and CBD have dominated cannabis research and consumer markets, scientists are increasingly turning their attention to so-called “minor” cannabinoids like CBG, which occur in much smaller concentrations in the plant. CBG is considered a precursor molecule—often dubbed the “mother cannabinoid”—from which THC, CBD, and other cannabinoids are biosynthesized. Though typically present in less than 1% in most cannabis strains, recent breeding techniques have enabled higher-yield CBG cultivars. Interest surged after preliminary studies hinted at anti-inflammatory, neuroprotective, and even anti-cancer properties. Now, its potential role in metabolic regulation has added a new dimension to its therapeutic profile. With obesity rates climbing globally and existing pharmacological treatments limited by side effects, the discovery of a naturally derived compound that suppresses appetite without impairing mental function could be a game-changer.

Study Details: How CBG Reduced Weight in Mice

The study, conducted at the University of Reading and published in March 2024, administered purified CBG to a cohort of mice over a six-day period. The treated group showed a consistent 30% reduction in food intake compared to the control group, resulting in significant body weight loss—despite no changes in physical activity or energy expenditure. Notably, CBG did not induce nausea or aversive behaviors, which are common drawbacks of other appetite suppressants. The researchers also observed changes in the expression of genes related to hunger signaling, particularly a downregulation of Npy (neuropeptide Y) in the hypothalamus, a brain region critical for appetite control. These findings suggest CBG may act directly on central metabolic pathways. The compound was well-tolerated, with no signs of toxicity or motor impairment, reinforcing its potential safety profile for future human trials.

Mechanisms and Metabolic Pathways Under Investigation

The precise mechanism by which CBG suppresses appetite remains under investigation, but early evidence points to its interaction with the endocannabinoid system (ECS), particularly CB1 receptors in the brain. Unlike THC, which activates CB1 receptors and stimulates hunger, CBG appears to act as a neutral antagonist or weak blocker, potentially preventing overactivation linked to increased appetite. This nuanced modulation could explain its appetite-suppressing effects without triggering anxiety or cognitive disruption. Additionally, CBG may influence peripheral metabolic tissues, including the liver and adipose tissue, though this requires further study. According to Dr. Oludoyin Awoyemi, co-author of the study, “CBG’s unique pharmacological profile allows it to fine-tune the ECS in a way that could correct metabolic imbalances without the downsides of current drugs.” Data from similar compounds suggest long-term use might improve insulin sensitivity and reduce fat accumulation.

Implications for Obesity Treatment and Public Health

If these findings translate to humans, CBG could become a cornerstone in the pharmacological management of obesity—a condition linked to heart disease, diabetes, and reduced life expectancy. Current appetite suppressants, such as semaglutide (marketed as Wegovy), are effective but come with gastrointestinal side effects and high costs. A naturally derived, well-tolerated alternative like CBG could broaden access and adherence. Moreover, its non-psychoactive nature removes regulatory and social barriers associated with THC-containing products. Patients with conditions like Prader-Willi syndrome, characterized by insatiable hunger, could particularly benefit. However, researchers caution that mouse models do not always predict human outcomes, and large-scale clinical trials are needed to confirm efficacy and safety in diverse populations.

Expert Perspectives

While the results are promising, some experts urge caution. Dr. Marsida Kajko of King’s College London notes, “CBG’s effects in humans may differ due to metabolic and neurological complexity not captured in rodent models.” Others highlight the risk of overhyping early-stage research, especially in a field as commercially charged as cannabis. Conversely, Dr. John MacKenzie, a neuropharmacologist at University College Dublin, calls the findings “a compelling pivot in cannabinoid science,” emphasizing that “we’re only beginning to unpack the therapeutic diversity of cannabis beyond THC and CBD.” The debate underscores the need for rigorous, independent clinical validation before CBG can be considered a viable treatment.

Looking ahead, researchers plan phase I human trials to assess CBG’s safety and pharmacokinetics in healthy volunteers. Key questions remain: What is the optimal dosage? How does long-term use affect metabolism? And can CBG be combined with other therapies for synergistic effects? As the science evolves, regulatory frameworks will need to adapt to accommodate non-psychoactive cannabinoids. With obesity projected to affect nearly 1 billion people by 2030, the stakes—and the potential—have never been higher.

Source: Earth